Sonoporation and UTMD for Augmenting Cancer Treatments
Monday, April 8, 2024
3:30pm – 4:00pm
Location: 408
CME 1.5
The use of gas filled microbubbles (1-10 micron in diameter) as vascular tracers and contrast agents for ultrasound imaging is well established. Such contrast agents are used worldwide to improve the diagnostic capabilities of contrast enhanced ultrasound imaging (CEUS). At higher acoustic pressures (albeit well within United States FDA limits) the microbubbles undergo stable cavitation followed by destruction via gas diffusion and inertial cavitation, which produces numerous, localized bioeffects. Among these bioeffects, microbubble cavitation can improve drug delivery and sensitize solid tumors to radiation. Our pre-clinical and clinical trials to investigate the safety and therapeutic benefits of combining radioembolization and ultrasound-triggered microbubble destruction (UTMD) in patients with hepatocellular carcinoma (HCC) as well as the possibility of improving antibiotic treatment of joint infections with UTMD will be discussed. The current status of our ongoing trial of sonoporation in patients with pancreatic ductal adenocarcinoma (PDAC) will be presented.